Payment overview · 2025
General Payments
$88.98
3 reported records · 3 companies
Healthcare provider profile · identity verified
Stephen R Simpson, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LAFAYETTE, LA · NPI 1235128026
Verified facts
What the public records show
CMS Open Payments records show Stephen R Simpson, MD received $88.98 in general payments during 2025 across 3 reported records.
ABIOMED accounted for 60.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $54.04 | 60.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.76 | 22.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.18 | 17.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.98 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1764 | 374 |
| Furosemide | Furosemide | 1697 | 372 |
| Amlodipine Besylate | Amlodipine Besylate | 1248 | 276 |
| Eliquis | Apixaban | 1137 | 182 |
| Carvedilol | Carvedilol | 911 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 148 |
| Clopidogrel | Clopidogrel Bisulfate | 704 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 619 | 143 |
| Lisinopril | Lisinopril | 595 | 132 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 580 | 129 |
| Losartan Potassium | Losartan Potassium | 579 | 130 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 393 | 80 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 378 | 77 |
| Warfarin Sodium | Warfarin Sodium | 356 | 58 |
| Xarelto | Rivaroxaban | 353 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 333 | 75 |
| Ranolazine Er | Ranolazine | 331 | 66 |
| Potassium Chloride | Potassium Chloride | 328 | 76 |
| Entresto | Sacubitril/Valsartan | 259 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 46 |
| Lovastatin | Lovastatin | 210 | 42 |
| Repatha Sureclick | Evolocumab | 197 | 25 |
| Torsemide | Torsemide | 196 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 184 | 39 |
| Spironolactone | Spironolactone | 180 | 57 |
| Enalapril Maleate | Enalapril Maleate | 167 | 37 |
| Ezetimibe | Ezetimibe | 154 | 36 |
| Digoxin | Digoxin | 140 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 134 | 31 |
| Chlorthalidone | Chlorthalidone | 123 | 27 |
| Simvastatin | Simvastatin | 117 | 22 |
| Bumetanide | Bumetanide | 114 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 113 | 31 |
| Valsartan | Valsartan | 105 | 23 |
| Irbesartan | Irbesartan | 104 | 24 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 100 | 26 |
| Benazepril Hcl | Benazepril Hcl | 95 | 22 |
| Tiadylt Er | Diltiazem Hcl | 93 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 87 | 20 |
| Midodrine Hcl | Midodrine Hcl | 82 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 18 |
| Metolazone | Metolazone | 79 | 18 |
| Nitroglycerin | Nitroglycerin | 79 | 46 |
| Flecainide Acetate | Flecainide Acetate | 76 | suppressed |
| Multaq | Dronedarone Hcl | 72 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 20 |
| Clonidine Hcl | Clonidine Hcl | 59 | 11 |
| Atenolol | Atenolol | 58 | 14 |
| Ramipril | Ramipril | 55 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 38 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 13 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Livalo | Pitavastatin Calcium | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 31 | suppressed |
| Sotalol | Sotalol Hcl | 30 | 12 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Cartia Xt | Diltiazem Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Verapamil Sr | Verapamil Hcl | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 13 |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Nexletol | Bempedoic Acid | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.98 · 3 records | ABIOMED | JARDIANCE, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error